Cost Effectiveness of Treatments for non-ST-segment elevation Acute Coronary Syndrome

Background Acute coronary syndrome (ACS) represents the most common subset of cardiovascular heart diseases and relates to high rates of morbidity and mortality worldwide and, consequently, to both the direct and indirect costs to the health system and society. Given the rising healthcare costs combined with budgetary constraints, health care systems and decision makers are faced with challenging decisions and the need to choose alternative treatments that not only improve patient quantity and quality of life but are also economically attractive.